...
首页> 外文期刊>Yonsei Medical Journal >Expression of biliary antigen and its clinical significance in hepatocellular carcinoma
【24h】

Expression of biliary antigen and its clinical significance in hepatocellular carcinoma

机译:胆道抗原在肝细胞癌中的表达及其临床意义

获取原文

摘要

In order to classify the hepatocellular carcinomas (HCCs) which had diverse clinicopathologic characteristics, we divided HCCs into two groups according to the expression of biliary antigen on the basis of the hypothesis that the hepatocyte and biliary epithelial cell originate from the same precursor cell, and then we investigated the clinical and pathologic characteristics in the two groups. Forty HCC cases with no preoperative treatment and at least two-year follow-up data were selected among 202 cases of HCC files from 1991 to 1995. Expression of biliary antigen (AE1, cytokeratin 19), p53, AFP, and Ki-67 in the tumor tissue were assessed by immunohistochemistry. Positive cytokeratin 19 was noted in one case (2.5%); AE1 was detected in 40% of patients; p53 was overexpressed in 20% of patients; and AFP was detected in 45% of patients. No statistical difference between the biliary antigen positive group (16 cases) and the negative group (24 cases) were noted in terms of mean age, sex, presurgical serum AFP level, Child class, and tumor size. HBsAg positive rate was 66.7% for the biliary antigen (-) group and 93.8% for the biliary antigen (+) group with a statistically significant difference (p = 0.048). The number of cases for Edmonson-Steiner grade I/II and III/IV were 15 and 9 in the biliary antigen (-) group, and 4 and 12 in the biliary antigen (+) group, respectively, with a statistically significant difference (p = 0.024). The 1, 3 and 5-year disease-free survival rates were 69.7, 40.9 and 40.9% for the biliary antigen (-) group and 73.7, 39.1, 39.1% for the biliary antigen (+) group with no statistically significant difference. The 1, 3 and 5-year overall survival rates were 91.7, 73.8, 66.4% for the biliary antigen (-) group and 68.8, 34.4, 34.4% for the biliary antigen (+) group, with a significantly greater overall survival rate for the biliary antigen negative group (p = 0.045). Poor histopathological differentiation, a high HBsAg positive rate and poor overall survival rate were noted in the biliary antigen positive group and the differences were statistically significant. In conclusion, HCCs with positive biliary antigen, which originates from more primitive cells, is suggested to be more aggressive than HCCs with negative biliary antigen.
机译:为了对具有不同临床病理特征的肝细胞癌(HCC)进行分类,我们基于肝细胞和胆道上皮细胞起源于同一前体细胞的假设,根据胆道抗原的表达将其分为两组。然后我们调查了两组的临床和病理特征。在1991年至1995年的202例HCC病例中选择了40例没有术前治疗并且至少进行两年随访的HCC病例。胆道抗原(AE1,细胞角蛋白19),p53,AFP和Ki-67的表达。通过免疫组织化学评估肿瘤组织。注意到细胞角蛋白19阳性(1%)(2.5%)。在40%的患者中检测到AE1; p53在20%的患者中过表达;在45%的患者中检测到AFP。胆道抗原阳性组(16例)和阴性组(24例)在平均年龄,性别,术前血清AFP水平,儿童等级和肿瘤大小方面没有统计学差异。胆道抗原(-)组的HBsAg阳性率为66.7%,胆道抗原(+)组的HBsAg阳性率为93.8%,具有统计学显着性差异(p = 0.048)。胆道抗原(-)组的Edmonson-Steiner I / II和III / IV级病例数分别为15和9,胆道抗原(+)组分别为4和12,差异有统计学意义( p = 0.024)。胆道抗原(-)组的1、3和5年无病生存率分别为69.7%,40.9和40.9%,胆道抗原(+)组的分别为73.7、39.1、39.1%,无统计学差异。胆道抗原(-)组的1年,3年和5年总生存率为91.7%,73.8%,66.4%,胆道抗原(+)组的1年,3年和5年总生存率分别为68.8%,34.4%和34.4%,其中胆汁抗原阴性组(p = 0.045)。胆汁抗原阳性组的组织病理学分化差,HBsAg阳性率高,总生存率差,差异具有统计学意义。总之,胆汁抗原阳性的HCC起源于更多原始细胞,被认为比胆汁抗原阴性的HCC具有更高的侵袭性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号